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Markov model was constructed to analyse CHB patients’ life
expectancy (LE) of no antiviral treatment versus 18-month, 36-
month, and unrestricted duration of lamivudine treatment, and
their associated reimbursement cost from Taiwan National
Health Insurance (TNHI) perspective. Disease progression, 
clinical effectiveness and patient population information were
obtained from systematic review of published studies. Costs of
medication, diagnostics, physician’s fees, and hospitalization
were included. Incremental cost-effectiveness ratios (ICERs)
compared to disease progression without antiviral treatment
were derived. The annual cost of lamivudine treatment was
based on a 10% recruitment rate from 120,000 eligible 30-year-
old CHB patients. All costs and health outcomes were discounted
at 3%. RESULTS: CHB without antiviral treatment results in LE
loss of 21.7 years for 30-year-old CHB patients. Lamivudine
used for 18-months, 36-months, and unrestricted treatment
duration could increase LE by 2.5, 4.0, and 5.1 years respec-
tively; continuing treatment in patients with cirrhosis could
increase LE by 10.2 years. Expected lifetime costs to the TNHI
for no antiviral treatment were US$12,854 per patient. Incre-
mental costs of using lamivudine for 18-month, 36-month, and
unrestricted duration were US$697, US$1031 and US$1278
respectively. ICERs for 18-month, 36-month, and unrestricted
were US$575.7, US$542.5, and US$530.3; and US$1820.4 for
treating cirrhotic patients. Expected maximal annual budget for
lamivudine was US$13.0m, US$15.3m, and US$15.3m for 18-
month, 36-month, and unrestricted respectively; and US$32.3m
for continuing treatment in cirrhotic patients. CONCLUSIONS:
CHB results in marked LE loss to patients. Lamivudine treat-
ment notably improves LE. The effectiveness of lamivudine
increased with increased treatment duration and when contin-
ued in cirrhotic patients. Long-term antiviral treatment of CHB
with lamivudine is a cost effective strategy in Taiwan with a man-
ageable impact on budgets.
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OBJECTIVES: To assess the cost-effectiveness of three tests for
HP detection in adults and develop decision analysis models to
compare “test—no test” strategies for the treatment of persistent
dyspepsia. METHODS: Two decision analytic models were con-
structed and analysed from the perspective of the health service.
The ﬁrst model was a simple decision tree of three types of HP
test, allowing for true and false test results, with the ‘number of
true outcomes’ as the measure of effectiveness. Tests considered
were the serological test, the C-urea breath test and the mono-
clonal faecal antigen test. The second model was based on pub-
lished guidelines for managing dyspepsia and procedures in
secondary care. Measures of effectiveness for the second model
include numbers in each end state, number of endoscopies per-
formed, and number of HP eradication treatments given inap-
propriately and the extent of wasted resources consumed. Data
used to furnish the models were gathered from the literature and
available published costs. RESULTS: The monoclonal faecal
antigen test was the most cost effective solution with an ICER
of £2 per additional true outcome, but was highly dependent on
the sensitivity and speciﬁcity of the serological test. The stool test
and the breath test either dominate or are relatively cost effec-
tive in relation to the serological test unless the speciﬁcity of the
serological test exceeds 0.93. The stool test either dominates or
is relatively cost effective in relation to serological test up to a
cost of £18.67 per stool test. Preliminary results from the second
model suggest that the decision is highly dependent on values
attached to the variables in the model, especially in relation to
costs of treatment and costs associated with malignancy. CON-
CLUSION: In the UK, the faecal antigen test is a cost effective
solution to testing for HP in dyspepsia patients.
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OBJECTIVES: To clarify whether the therapy of liver cirrhosis
with silymarin shows a higher cost-effectiveness than a treatment
without from of the third party payerxs perspective.
METHODS: To calculate the incremental cost-effectiveness
based upon a clinical study, the liver-related mortality rates of
patients with liver cirrhosis after four years, treated with or
without silymarin, were compared. Adverse effects (AE) and
adverse drug reactions (ADR) were also be considered. Com-
parative parameters were costs, effectiveness and tolerability of
both alternatives. Costs were generated by the drug therapy of
liver cirrhosis, medical care, and treatments of AE and ADR,
which were derived from previous studies and portrayed in a
core-model. The calculation of the model was performed by util-
ising the program DATA Professional. Two sensitivity-analyses
were conducted. RESULTS: For liver-related mortality total costs
of €5467 for silymarin and €3333 without silymarin were gen-
erated. The effectiveness-adjusted costs were calculated at €5970
for silymarin and €4009 for treatment without silymarin. This
entails that for the longer survival time of 9.12 months, incre-
mental costs of €1961 were calculated per silymarin patient.
However, as an effect, less AEs occurred and longer survival of
patients could be achieved with silymarin treatment of liver cir-
rhosis. CONCLUSION: With silymarin treatment of liver cir-
rhosis less AEs and longer survival of patients could be achieved.
By considering the concept of prolonged life, cost amounting to
€2580 was estimated per life year gained (lyg).
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OBJECTIVES: Peginterferon alfa-2b (12KD)/ribavirin (PEG2b)
has been shown to produce a higher rate of sustained virologi-
cal response (SVR) than non-pegylated combination therapy
(non-PEG) in CHC, but the cost effectiveness of this improved
efﬁcacy has not been assessed in Brazil. METHODS: We devel-
oped a Markov model to describe the clinical history of CHC in
which the cohorts of hepatitis C virus (HCV) patients received
PEG2B or non-PEG for either 48 or 24 weeks according to geno-
type and liver histology and were followed for their expected life-
time. The reference patient was a 30-year-old male with CHC
without cirrhosis. The SVRs to PEG2B and non-PEG were 48%
and 34% for HCV genotype 1 and 88% and 80% for non-1,
respectively. Quality of life for each health state was based on
literature. Costs for each health state were based on three Delphi
panels, one with hepatologists, one with intensivists and another
with oncologists. Costs in 2004 reais and beneﬁts were dis-
counted at 3%. RESULTS: In HCV genotype 1, PEG2B increases
life expectancy (LY) by 1.79 years and quality adjusted life
expectancy (QALY) by 0.82 years compared to non-PEG. The
